Originalarbeiten

1. Augustin M, Reich K, Reusch M, Luger T, Franzke N, Schäfer I, Rustenbach SJ, Radtke MA. Health Services Research in Psoriasis - The German Approach.
Dermatology. 2009 Mar 6. [Epub ahead of print] 

2. Mössner R, Stiens G, König IR, Schmidt D, Platzer A, Krüger U, Reich K.
Analysis of a functional serotonin transporter promoter polymorphism in psoriasis vulgaris. Arch Dermatol Res. 2008 Nov 1. [Epub ahead of print]

3. Radtke MA, Reich K, Blome C, Kopp I, Rustenbach SJ, Schäfer I, Augustin M.
Evaluation of Quality of Care and Guideline-Compliant Treatment in Psoriasis. Development of a New System of Quality Indicators. Dermatology. 2009 May 7.  [Epub ahead of print] 

4. Radtke M, Reich K, Blome C, Rustenbach S, Augustin M. Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: results of a German national survey. J Eur Acad Dermatol Venereol.

2009 Mar 4. [Epub ahead of print]

5. Hauschild A, Stockfleth E, Popp G, Borrosch F, Brüning H, Dominicus R, Mensing H, Reinhold U, Reich K, Moor AC, Stocker M, Ortland C, Brunnert M, Szeimies RM. Optimization of photodynamic therapy with a novel self-adhesive 5-aminolaevulinic acid patch: results of two randomized controlled phase III studies.Br J Dermatol. 2009;160(5):1066-74.

6. Hüffmeier U, Lascorz J, Böhm B, Lohmann J, Wendler J, Mössner R, Reich K, Traupe H, Kurrat W, Burkhardt H, Reis A. Genetic variants of the IL-23R pathway: association with psoriatic arthritis and psoriasis vulgaris, but no specific risk factor for arthritis. J Invest Dermatol. 2009;129(2):355-8.

7. Reich K, Krüger K, Mössner R, Augustin M. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol. 2009;160(5):1040-7. 

8. Reich K. Wirksamkeit und Sicherheit des humanen monoklonalen Interleukin-12/23-Antikörpers Ustekinumab bei Patienten mit Psoriasis: Ergebnisse der randomisierten, doppel-blinden, plazebokontrollierten Phase-III-Studien PHOENIX 1 und PHOENIX 2. Akt Dermatol. 2009;35(1/2):29-34. 

9. Mease PJ, Reich K. Alefacept with methotrexate for treatment of psoriatic arthritis: open-label extension of a randomized, double-blind, placebo-controlled study. J Am Acad Dermatol. 2009;60(3):402-11.

10. van de Kerkhof PC, Hoffmann V, Anstey A, Barnes L, Bolduc C, Reich K, Saari S, Segaert S, Vaillant L. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. Br J Dermatol. 2009 Jan;160(1):170-6.

11. Augustin M, Krüger K, Radtke MA, Schwippl I, Reich K. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology. 2008;216(4):366-72. 

12. Augustin M, Reich K, Reich C, Purwins S, Jeff Rustenbach S, Schäfer I, Radtke 

M. Quality of psoriasis care in Germany - results of the national study PsoHealth 2007. J Dtsch Dermatol Ges. 2008;6(8):640-5.

13. Chang YM, Newton-Bishop JA, Bishop DT, Armstrong BK, Bataille V, Bergman W, Berwick M, Bracci PM, Elwood JM, Ernstoff MS, Green AC, Gruis NA, Holly EA, Ingvar C, Kanetsky PA, Karagas MR, Marchand LL, Mackie RM, Olsson H, Osterlind A, Rebbeck TR, Reich K, Sasieni P, Siskind V, Swerdlow AJ, Titus-Ernstoff L, Zens MS, Ziegler A, Barrett JH. A pooled analysis of melanocytic nevus phenotype and the risk of cutaneous melanoma at different latitudes. Int J Cancer. 2008;124(2):420-8.

14. Haenssle H, Buhl T, Knudsen S, Krueger U, Rosenberger A, Reich K, Neumann C. CD40 ligation during dendritic cell maturation reduces cell death and prevents interleukin-10-induced regression to macrophage-like monocytes. Exp Dermatol. 2008;17(3):177-87. 

15. Kingo K, Mössner R, Rätsep R, Raud K, Krüger U, Silm H, Vasar E, Reich K, Kõks S. Association analysis of IL20RA and IL20RB genes in psoriasis. Genes Immun. 2008;9(5):445-51.

16. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, Hsu MC, Wang Y, Li S, Dooley LT, Reich K; PHOENIX 2 study investigators.

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008 ;371(9625): 1675-84.

17. Reich K, Griffiths C, Barker J, Chimenti S, Daudén E, Gianetti A, Gniadecki R, Katsambas A, Langley R, Mrowietz U, Ogilvie A, Ortonne JP, Reider N, Saurat JH. Recommendations for the long-term treatment of psoriasis with infliximab: a dermatology expert group consensus. Dermatology. 2008;217(3):268-75. 

18. Rich P, Griffiths CEM, Reich K, Nestle FO, Scher RK, Li S, Xu S, Hsu MC, Guzzo C. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol. 2008;58(2):224-31. 

19. Zschocke I, Reich C, Zielke A, Reitmeier N, Reich K. Silica gel is as effective as acyclovir cream in patients with recurrent herpes labialis: results of a randomized, open-label trial. J Dermatolog Treat. 2008;19(3):176-81.

20. Kingo K, Mössner R, Kõks S, Rätsep R, Krüger U, Vasar E, Reich K, Silm H. Association analysis of IL19, IL20 and IL24 genes in palmoplantar pustulosis. Br J Dermatol. 2007;156(4):646-52. 

21. Mössner R, Anders N, König IR, Krüger U, Schmidt D, Berking C, Ziegler A, Brockmöller J, Kaiser R, Volkenandt M, Westphal GA, Reich K. Variations of the melanocortin-1 receptor and the glutathione-S transferase T1 and M1 genes in cutaneous malignant melanoma. Arch Dermatol Res. 2007;298(8):371-9.

22. Mössner R, Meyer P, Jankowski F, König IR, Kruger U, Kammerer S, Westphal G, Boettger MB, Berking C, Schmitt C, Brockmöller J, Ziegler A, Stapelmann H, Kaiser R, Volkenandt M, Reich K. Vatiations in the peroxisome proliferator-activated receptor-gamma gene and melanoma risk. Cancer Lett. 2007;246(1-2):218-23.

23. Niedermeier A, Eming R, Pfütze M, Neumann CR, Happel C, Reich K, Hertl M. Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibodies). Arch Dermatol. 2007;143(2):192-8.

24. Reich K, Huffmeier U, König IR, Lascorz J, Lohmann J, Wendler J, Traupe H, Mössner R, Reis A, Burkhardt H. TNF polymorphisms in psoriasis: association of psoriatic arthritis with the promoter polymorphism TNF*-857 independent of the PSORS1 risk allele. Arthritis Rheum. 2007;56(6):2056-2064.

25. Reich K, Nestle FO, Wu Y, Bala M, Eisenberg D, Guzzo C, Li S, Dooley LT, Griffiths CE. Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis. Eur J Dermatol. 2007;17(5):381-6.

26. Schöffski O, Augustin M, Prinz J, Rauner K, Schubert E, Sohn S, Reich K. Krankheitskosten und Lebensqualität bei Patienten mit mittelschwerer bis schwerer Psoriasis vulgaris in Deutschland: eine multizentrische Studie. J Dtsch Dermatol Ges. 2007;5(3):209-19.

27. Huffmeier U, Steffens M, Burkhardt H, Lascorz J, Schurmeier-Horst F, Stander M, Kelsch R, Baumann C, Kuster W, Mössner R, Reich K, Wienker TF, Traupe H, Reis A. Evidence for susceptibility determinant(s) to psoriasis vulgaris in or near PTPN22 in German patients. J Med Genet. 2006;43(6):517-22.

28. Reich K, Nestle FO, Papp K, Ortonne JP, Wu Y, Bala M, Evans R, Guzzo CA, Li S, Dooley LT, Griffiths CE. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate- to-severe psoriasis: a randomized controlled trial. Brit J Dermatol. 2006;154(6):1161-8.

29. Sohn S, Schoeffski O, Prinz J, Reich K, Schubert E, Waldorf K, Augustin M. Cost of moderate-to-severe plaque-psoriasis in Germany: a multicentre cost-of-illness study. Dermatology. 2006;212(2):137-44.

30. Blankenburg S, König IR, Mössner R, Laspe P, Thoms KM, Krüger U, Khan SG, Westphal G, Berking C, Volkenandt M, Reich K, Neumann C, Ziegler A, Kraemer KH, Emmert S. Assessment of 3 xeroderma pigmentosum group C gene polymorphisms and risk of cutaneous melanoma: a case-control study. Carcinogenesis. 2005;26(6):1085-90. 

31. Blankenburg S, König IR, Mössner R, Laspe P, Thoms KM, Krüger U, Khan SG, Westphal G, Volkenandt M, Neumann C, Ziegler A, Kraemer KH, Reich K, Emmert S. No association between three xeroderma pigmentosum group C and one group G gene polymorphisms and risk of cutaneous melanoma. Eur J Hum Genet. 2005;13(2):253-5.  

32. Distler JH, Jungel A, Kowal-Bielecka O, Michel BA, Gay RE, Sprott H, Matucci-Cerinic M, Chilla M, Reich K, Kalden JR, Muller-Ladner U, Lorenz HM, Gay S, Distler O. Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis. Arthritis Rheum. 2005;52(3):856-64.

33. Mössner R, Kingo K, Kleensang A, Krüger U, König IR, Silm H, Westphal GA, Reich K. Association of TNF -238 and -308 promoter polymorphisms with psoriasis vulgaris and psoriatic arthritis but not with pustulosis palmoplantaris. J Invest Dermatol. 2005;124(1):282-4. 

34. Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CE. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366(9494):1367-74.

35. Mössner R, Beckmann I, Hallermann C, Neumann C, Reich K. Granulocyte colony-stimulating-factor-induced psoriasiform dermatitis resembles psoriasis with regard to abnormal cytokine expression and epidermal activation. Exp Dermatol. 2004;13(6):340-6. 

36. Mössner R, Kaiser R, Matern P, Kruger U, Westphal GA, Brockmöller J, Ziegler A, Neumann C, König IR, Reich K. Variations in the genes encoding the peroxisome proliferator-activated receptors alpha and gamma in psoriasis. Arch Dermatol Res. 2004;296(1):1-5. 

37. Mössner R, Tings T, Beckmann I, Neumann C, Paulus W, Reich K. A close look at autoimmune muscle disorders: association of Lambert-Eaton myasthenic syndrome with dermatomyositis. Scand J Rheumatol. 2004;33(4):271-5. 

38. Reich K, Hugo S, Middel P, Blaschke V, Heine A, Neumann C. The maturation-dependent production of interleukin-16 is impaired in monocyte-derived dendritic cells from atopic dermatitis patients but is restored by inflammatory cytokines TNF-alpha and IL-1beta. Exp Dermatol. 2004;13(12):740-7. 

39. Blaschke S, Middel P, Dorner BG, Blaschke V, Hummel KM, Kroczek RA, Reich K, Benoehr P, Koziolek M, Muller GA. Expression of activation-induced, T cell-derived, and chemokine-related cytokine/lymphotactin and its functional role in rheumatoid arthritis. Arthritis Rheum. 2003;48(7):1858-72. 

40. Reich K, Westphal GA, König IR, Mössner R, Krüger U, Ziegler A, Neumann C, Schnuch A. Association of allergic contact dermatitis with a promoter polymorphism in the IL16 gene. J Allergy Clin Immunol. 2003;112(6):1191-4. 

41. Reich K, Westphal GA, König IR, Mössner R, Schupp P, Gutgesell C, Hallier E, Ziegler A, Neumann Ch. Cytokine gene polymorphisms in atopic dermatitis. Br J Dermatol. 2003;148(6):1237-41.

42. Westphal GA, Schnuch A, Mössner R, König IR, Kränke B, Hallier E, Ziegler A, Reich K. Cytokine gene polymorphisms in allergic contact dermatitis. Contact Dermatitis. 2003;48(2):93-8.

43. Blaschke V, Reich K, Blaschke S, Zipprich S, Neumann C. Quantitative RT-PCR: comparing real-time lightcycler technology with quantitative competitive RT-PCR. Biochemica. 2002;(1):6-8.

44. Mössner R, Schulz U, Krüger U, Middel P, Schinner S, László Fuzesi L, Neumann C, Reich K. Agonists of peroxisome proliferator-activated receptor gamma inhibit cell growth in malignant melanoma. J Invest Dermatol. 2002;119(3):576-82.

45. Reich K, Hugo S, Middel P, Blaschke V, Heine A, Gutgesell C, Williams R, Neumann Ch. Evidence for a role of Langerhans cell-derived interleukin-16 in atopic dermatitis. J Allergy Clin Immunol. 2002;109(4):681-7.

46. Reich K, Mössner R, König IR, Westphal G, Ziegler A, Neumann Ch. Promoter polymorphisms of the genes encoding tumor necrosis factor-alpha and interleukin-1beta are associated with different subtypes of psoriasis characterized by early and late disease onset. J Invest Dermatol. 2002;118(1):155-63.

47. Middel P, Reich K, Polzien F, Blaschke V, Hemmerlein B, Herms J, Korabiowska M, Radzun HJ. Interleukin-16 expression and phenotype of interleukin-16 producing cells in Crohn's disease. Gut. 2001;49(6):795-803. 

48. Middel P, Thelen P, Blaschke S, Polzien F, Reich K, Blaschke V, Wrede A, Hummel KM, Gunawan B, Radzun HJ. Expression of the T-cell chemoattractant chemokine lymphotactin in Crohn's disease. Am J Pathol. 2001;159(5):1751-61.

49. Reich K, Garbe C, Blaschke V, Maurer C, Middel P, Westphal G, Lippert U, Neumann Ch. Response of psoriasis to interleukin-10 is associated with suppression of cutaneous type 1 inflammation, downregulation of the epidermal IL-8/CXCR2 pathway and normalization of keratinocyte maturation. J Invest Dermatol. 2001;116(2):319-29. 

50. Reich K, Heine A, Hugo S, Blaschke V, Middel P, Kaser A, Tilg H, Blaschke S, Gutgesell C, Neumann Ch. Engagement of the high affinity IgE receptor, FcεRI, stimulates the production of IL-16 in Langerhans cell-like dendritic cells.  J Immunol. 2001;167(11):6321-9.

51. Blaschke V, Reich K, Blaschke S, Zipprich S, Neumann Ch. Rapid quantitation of proinflammatory and chemoattractant cytokine expression in small tissue samples and monocyte-derived dendritic cells, Validation of a new real-time RT-PCR technology. J Immunol Methods. 2000;246(1-2):79-90.

52. Westphal GA, Reich K, Schulz TG, Neumann Ch, Hallier E, Schnuch A. N-acetyltransferases 1 and 2 polymorphisms in para-substituted arylamine-induced contact allergy. Br J Dermatol. 2000;142(6):1121-7.

53. Westphal GA, Schnuch A, Schulz TG, Reich K, Aberer W, Brasch J, Koch P, Wessbecher R, Szliska C, Bauer A, Hallier E. Homozygous gene deletions of the glutathione S-transferases M1 and T1 are associated with thimerosal sensitization. Int Arch Occup Environ Health. 2000;73(6):384-8.

54. Blaschke V, Reich K, Middel P, Letschert M, Sachse F, Harwix S, Neumann Ch. Expression of the CD4+ cell-specific chemoattractant interleukin-16 in mycosis fungoides. J Invest Dermatol. 1999;113(4):658-63. 

55. Reich K, Brinck U, Letschert M, Blaschke V, Dames K, Braess J, Wörmann B, Rünger TM, Neumann Ch. Graft-versus-host disease-like cutaneous immunophenotype and apoptotic keratinocyte death in paraneoplastic pemphigus. Br J Dermatol. 1999;141(4):739-46 .

56. Reich K, Westphal GA, Schulz TG, Müller M, Zipprich S, Fuchs Th, Hallier E, Neumann Ch. Combined analysis of polymorphisms of the tumor necrosis factor-alpha and interleukin-10 promoter regions and polymorphic xenobiotic metabolizing enzymes in psoriasis. J Invest Dermatol. 1999;113(2):214-20.

57. Vente C, Reich K, Rupprecht R, Neumann Ch. Erosive mucosal lichen planus, response to topical treatment with tacrolimus. Br J Dermatol. 1999;140(2):338-42. 

58. Reich K, Brück M, Gräfe A, Vente C, Neumann Ch, Garbe C. Treatment of psoriasis with interleukin-10. J Invest Dermatol. 1998;111(6):1235-6. [letter]

59. Schnuch A, Westphal GA, Müller MM, Schulz TG, Geier J, Brasch J, Merk HF, Kawakubo Y, Richter G, Koch P, Fuchs Th, Gutgesell C, Reich K, Gebhardt M, Becker D, Grabbe J, Sziska C, Aberer W, Hallier E. Genotype and phenotype of N-acetyltransferase 2 (NAT2): polymorphism in patients with contact allergy. Contact Dermatitis. 1998;38(4):209-11. 

60. Boxberger HJ, Meyer TF, Grausam MC, Reich K, Becker HD, Sessler MJ. Isolating and maintaining highly polarized primary epithelial cells from normal human duodenum for growth as spheroid-like vesicles. In Vitro Cell Dev Biol Anim. 1997;35(7):536-45. 

61. Braess J, Reich K, Willert S, Strutz F, Neumann Ch, Hiddemann W, Wörmann B. Mucocutaneous autoimmune syndrome following fludarabine therapy for low-grade non-Hodgkin´s lymphoma of B-cell type (B-NHL). Ann Hematol. 1997;75(5-6):227-30.

62. Seifarth C, Deusch K, Reich K, Classen M. Local cellular immune response in Helicobacter pylori associated type B-gastritis - selective increase of CD4+ but not gamma/delta T-cells in the immune response to H. pylori antigens.  Z Gastroenterol. 1996;34(4):215-24. 

63. Reich K, Dähne I, Endres N, Classen M, Deusch K. Biased T-cell receptor V-beta repertoire of intestinal CD8+ T-cells in HIV-disease. Adv Exp Med Biol. 1995;371B:1023-6.

64. Seifarth C, Funk A, Reich K, Dähne I, Classen M, Deusch K. Selective increase of CD4+ and CD25+ T-cells but not of gamma/delta T-cells in H  pylori associated gastritis. Adv Exp Med Biol. 1995;371B:931-4. 

65. Van-Kerckhove C, Russel GJ, Deusch K, Reich K, Bhan AK, DerSimonian H, Brenner MB. Oligoclonality of human intestinal intraepithelial T-cells. J Exp Med. 1992;175(1):57-63. 

66. Deusch K, Lüling F, Reich K, Classen M, Wagner H, Pfeffer K. A major fraction of human intraepithelial lymphocytes simultaneously expresses the gamma/delta T-cell receptor, the CD8 accessory molecule and preferentially uses the V-delta 1 gene segment. Eur J Immunol. 1991;21(4):1053-9. 

67. Deusch K, Pfeffer K, Reich K, Gstettenbauer M, Daum S,  Lüling F, Classen M. Phenotypic and functional characterization of human TCR gamma/delta+ intestinal intraepithelial lymphocytes. Curr Top Microbiol Immunol. 1991;173:279-83. 


Übersichtsarbeiten

1. Shakery K, Reich K. Psoriasis – Krankheitsbild und aktuelle Therapie der Schuppenflechte. Med Monatsschr Pharm. [Epub ahead of print]

2. Mrowietz U, Klein CE, Reich K, Rosenbach T, Ruzicka T, Sebastian M, Werfel T.  Cyclosporine therapy in dermatology. J Dtsch Dermatol Ges. 2009 Mar 17. [Epub ahead of print]

3. Mrowietz U, Reich K. Psoriasis – neue Erkenntnisse zur Pathogenese und Therapie. Dtsch Arztebl. 2009; 106(1-2):11-9.

4. Reich K. Approach to managing patient with nail psoriasis. JEADV. 2009; 23(Suppl. 1):15-21.

5. Reich K, Yasothan U, Kirkpatrick P. Ustekinumab. Nat Rev Drug Discov. 2009;8(5):355-6.

6. Shakery K,  Mrowietz U, Reich K. Psoriasis und das metabolische Syndrom: Viel mehr als eine Hautkrankheit. Dt. Dermatologe. 2009;57(5):307-11.

7. Shakery K, Reich K. Nagelpsoriasis – ein Fingerzeig. ÄP Dermatologie Allergologie. 2009;(4):35-7.

8. Shakery K, Reich K. Psoriasis – State of the Art. Kompendium Dermatologie. 2009; 5(1):2-4.

9. Finlay AY, Reich K. Outcome assessment and treatment goals. Expert Rev Dermatol. 2008; 3(4s):S39-S40.

10. Hunzelmann N, Genth E, Krieg T, Lehmacher W, Melchers I, Meurer M, Moinzadeh P, Müller-Ladner U, Pfeiffer C, Riemekasten G, Schulze-Lohoff E, Sunderkoetter C, Weber M, Worm M, Klaus P, Rubbert A, Steinbrink K, Grundt B, Hein R, Scharffetter-Kochanek K, Hinrichs R, Walker K, Szeimies RM, Karrer S, Müller A, Seitz C, Schmidt E, Lehmann P, Foeldvári I, Reichenberger F, Gross WL, Kuhn A, Haust M, Reich K, Böhm M, Saar P, Fierlbeck G, Kötter I, Lorenz HM, Blank N, Gräfenstein K, Juche A, Aberer E, Bali G, Fiehn C, Stadler R, Bartels V; Registry of the German Network for Systemic Scleroderma. The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement. Rheumatology (Oxford). 2008; 47(8):1185-92. 

11. Menter A, Reich K, Gottlieb AB, Bala M, Li S, Hsu MC, Guzzo C, Diels J, Gelfand JM. Adverse drug events in infliximib-treated patients compared with the general and psoriasis populations. J Drugs Dermatol. 2008; 7(12):1137-46.

12. Reich K. Keynote lecture: psoriasis update. Expert Rev Dermatol. 2008; 3(4s):S3-S9.

13. Reich K, Griffiths C, Barker J, Chimenti S, Daudén E, Giannetti A, Gniadecki

R, Katsambas A, Langley R, Mrowietz U, Ogilvie A, Ortonne JP, Reider N, Saurat JH. Recommendations for the long-term treatment of psoriasis with infliximab: a dermatology expert group consensus. Dermatology. 2008; 217(3):268-75. 

14. Reich K, Griffiths CE. The relationship between quality of life and skin clearance in moderate-to-severe psoriasis: lessons learnt from clinical trials with infliximab. Arch Dermatol Res. 2008; 300(10):537-44.

15. Mössner R, Schön MP, Reich K. Tumor necrosis factor antagonists in the therapy of psoriasis. Clin Dermatol. 2008; 26(5):486-502.

16. Reich K, Sinclair R, Roberts G, Griffiths CE, Tabberer M, Barker J. Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis. Curr Med Res Opin. 2008; 24(5):1237-54. 

17. Reich K, Menter A, Plotnick M, Guzzo C, Li S, Gottlieb A. Consistency of Infliximab response across subgroups of patients with psoriasis. Integrated results from randomized clinical trials. Psoriasis Forum. 2007; 13:21-7.

18. Radtke MA, Mössner R, Augustin M, Reich K. Psoriasis-Arthritis. Therapeutische Strategien: je früher desto besser. Der Deutsche Dermatologe. 2007;55(6):1-4.

19. Radtke MA, Mössner R, Augustin M, Reich K. Psoriasis-Arthritis. Klinik, Pathogenese und Diagnostik. Der Deutsche Dermatologe. 2007;55(5):327-33.

20. Reich K, Mrowietz M. Therapieziele bei der Behandlung der Psoriasis. J Dtsch Dermatol Ges. 2007;5(7):566-574.

21. Roll A, Reich K, Böer A. Use of fumaric acid esters in psoriasis. Indian J Dermatol Venereol Leprol. 2007;73(2):133-7.

22. Boehncke WH, Friedrich M, Kaltwasser JP, Manger B, Mrowietz U, Reich K, Rosenbach T. Psoriasis-Arthritis: eine interdisziplinäre Herausforderung. Dtsch Arztebl. 2006;103(21):1455-61.

23. Distler M, Distler J, Ciurea A, Kyburz D, Müller-Ladner U, Reich K, Distler O. Evidenzbasierte Therapie des Raynaud-Syndroms. Z Rheumatol. 2006;65(4):285-9.

24. Mössner R, Reich K. Biologics in der Therapie der Psoriasis: unerwünschte Effekte an der Haut. Allergo J. 2006;15(7):492-500.

25. Mössner R, Reich K. Infliximab in the treatment of psoriasis. Expert Rev Dermatol. 2006;1(4):515-26.

26. Reich K. Is your psoriais patient a candidate for biologic therapy? Skin & Allergy News. 2006;Suppl:10-1.

27. Schröder JM, Reich K, Kabashima K, Liu FT, Romani N, Metz M, Kerstan A, Lee PHA, Loser K, Schön MP, Maurer M, Stoitzner P, Beissert S, Tokura Y, Gallo RL. Who is really in control of skin immunity under physiological circumstances – lymphocytes, dendritic cells or keratinocytes? Exp Dermatol. 2006;15(11):913-29.

28. Mössner R, Reich K. Infliximab: Stellenwert in der Therapie der Psoriasis. Hautarzt. 2005;56(9):831-8.

29. Mössner R, Reich K. Pathogenetische Aspekte der Psoriasis-Arthritis. Haut. 2005;(1): 19-24.

30. Reich K, Augustin M. Biologics in der Therapie der Psoriasis. Arzneimitteltherapie. 2005;23(12):384-97.

31. Reich K, Mössner R. Enthesitis – Entzündung an den Sehnenansätzen: Mechanismus und Manifestation. Pso Magazin. 2005;31(3):12-3.

32. Boehncke WH, Friedrich M, Mrowietz U, Reich K, Rosenbach T, Sticherling M, Thaci D. The role of biologics in the management of psoriasis: a consensus paper by the Psoriasis Study Group, Arbeitsgemeinschaft Dermatologische Forschung. J Dtsch Dermatol Ges. 2003;1(8):620-8. 

33. Reich K. Die Haut als Spiegel des Immunsystems. Der Dialysepatient. 2003;9 (Sonderheft):17-21.

34. Reich K. Regulatory functions of IL-10 in the cutaneous immune system, a lesson to learn from experimental IL-10 therapy of inflammatory skin disease. G Ital Dermatol Venereol. 2001;136:351-70.

35. Deusch K, Reich K. Immunological aspects of inflammatory bowel disease. Endoscopy. 1992;24(10):568-77.

Leitlinien

1. Nast A, Kopp IB, Augustin M, Banditt KB, Boehncke WH, Follmann M, Friedrich M, Huber M, Kahl C, Klaus J, Koza J, Kreiselmaier I, Mohr J, Mrowietz U, Ockenfels HM, Orzechowski HD, Prinz J, Reich K, Rosenbach T, Rosumeck S, Schlaeger M, Schmid-Ott G, Sebastian M, Streit V, Weberschock T, Rzany B; Deutsche Dermatologische Gesellschaft (DDG); Berufsverband Deutscher Dermatologen (BVDD). Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris. J Dtsch Dermatol Ges.2007;5 Suppl 3:1-119.

2. Nast A, Kopp IB, Augustin M, Banditt KB, Boehncke WH, Follmann M, Friedrich M, Huber M, Kahl C, Klaus J, Koza J, Kreiselmaier I, Mohr J, Mrowietz U, Ockenfels HM, Orzechowski HD, Prinz J, Reich K, Rosenbach T, Rosumeck S, Schlaeger M, Schmid-Ott G, Sebastian M, Streit V, Weberschock T, Rzany B. German evidence-based guidelines for the treatment of Psoriasis vulagris (short version). Arch Dermatol Res. 2007;299(3):111-38.

3. Mrowietz U, Barth J, Boehncke WH, Reich K, Rosenbach T, Streit V, Wozel G. Therapie der Psoriasis-Arthritis und der Psoriasis vulgaris mit Infliximab. J Dtsch Dermatol Ges. 2006;4(5):444-7.

4. Mrowietz U, Barth J, Boehncke WH, Reich K, Rosenbach T, Streit V, Wozel G. Therapie der Psoriasis vulgaris mit Efalizumab. J Dtsch Dermatol Ges. 2006;4(6):511-2.

5. Nast A, Kopp IB, Augustin M, Banditt KB, Boehncke WH, Follmann M, Friedrich M, Huber M, Kahl C, Klaus J, Koza J, Kreiselmaier I, Mohr J, Mrowietz U, Ockenfels HM, Orzechowski HD, Prinz J, Reich K, Rosenbach T, Rosumeck S, Schlaeger M, Schmid-Ott G, Sebastian M, Streit V, Weberschock T, Rzany B. S3-Leitlinie zur Therapie der Psoriasis vulgaris. J Dtsch Dermatol Ges. 2006;4 Suppl 2:S1-S126.

6. Nast A, Kopp IB, Augustin M, Banditt KB, Boehncke WH, Follmann M, Friedrich M, Huber M, Kahl C, Klaus J, Koza J, Kreiselmaier I, Mohr J, Mrowietz U, Ockenfels HM, Orzechowski HD, Prinz J, Reich K, Rosenbach T, Rosumeck S, Schlaeger M, Schmid-Ott G, Sebastian M, Streit V, Weberschock T, Rzany B. Evidenzbasierte (S3) Leitlinie zur Therapie der Psoriasis vulgaris. Der Deutsche Dermatologe. 2006;54(11):769-76.

7. Follmann M, Sterry W, Rzany B, Boehncke WH, Weberschock T, Friedrich M, Mrowietz U, Kreiselmaier I, Ockenfels HM, Prinz J, Reich K, Mohr J, Rosenbach T, Schlaeger M, Sebastian M, Streit V. Erarbeitung der evidenzbasierten Leitlinie zur Psoriasis vulgaris : ein Projekt der Deutschen Dermatologischen Gesellschaft (DDG). J Dtsch Dermatol Ges. 2005;3(9):678-89. 


Kasuistiken

1. Mössner R, Thaci D, Mohr J, Pätzold S, Bertsch HP, Krüger U, Reich K. Manifestation of palmoplantar pustulosis during or after infliximab therapy for plaque-type psoriasis: report on five cases. Arch Dermatol Res. 2008;300(3):101-5.

2. Reitmeier N, Böer A, Broyer J, Reich K. Schwerste generalisierte Psoriasis beim Kleinkind: Therapieversuch mit Etanercept. In: Herbsttagung der Hamburger Dermatologischen Gesellschaft; 2006 Nov 29; Hamburg, Germany. Derm. 2006(12):36-9.

3. Reich K, Hummel KM, Beckmann I, Mossner R, Neumann Ch. Treatment of severe psoriasis and psoriatic arthritis with leflunomide. Br J Dermatol. 2002;146(2):335-6.

4. Gräfe A, Vente C, Reich K, Hallermann Ch, Neumann Ch. Wegenersche Granulomatose unter dem klinischen Bild einer Vasculitis allergica. Akt Dermatol. 2001;27(10):323-7.

5. Fischer T, Schwörer H, Vente C, Reich K, Ramadori G. Clinical improvement of HIV-associated psoriasis parallels a reduction of HIV viral load induced by effective antiretroviral therapy. Aids. 1999;13(5):628-9. [letter]

6. Reich K, Vente C, Neumann Ch. Topical tacrolimus for pyoderma gangrenosum. Br J Dermatol. 1998;139(4):755-7. [letter]


Buchbeiträge

1. Mössner R, Reich K. Management of severe psoriasis with TNF antagonists. Adalimumab, Etanercept and Infliximab. In: Yawalkar N, editors. Management of psoriasis (Current problems in dermatology ; 38). Basel: Karger; 2009. p.107-136.

2. Augustin M, Reich K, Radtke MA, Dierks C. Lebensqualität, Compliance und Empowerment bei Psoriasis. Bremen: UNI-MED; 2007.

3. Reich K, Schmidt G. Dermatika. In: Estler CJ, Schmidt H, editors. Pharmakologie und Toxikologie, 6th ed. Stuttgart: Schattauer; 2006. p. 943-961.

4. Schnuch A, Uter W, Reich K. Allergic contact dermatitis and atopic eczema. In: Ring J, Przybilla B, Ruzicka T, editors. Handbook of atopic eczema, 2nd ed. Berlin:  Springer; 2005. p. 176-99.

5. Deusch K, Lüling F, Reich K, Classen M. CD8+ gamma/delta cells (TCR1+CD8+) are a major population of human intraepithelial lymphocytes. In: Tsuchiya M et al., editors. Frontiers in mucosal immunology. Excerpta Medica International Congress Series. Amsterdam: Elsevier Science; 1991. p. 145-6.

6. Deusch K, Pluschke G, Wagner F, Köhne G, Daum S, Reich K, Pfeffer K, Classen M. T-Zellrezeptorrepertoire und Zytokinproduktion von humanen Darmlymphozyten. In: Seifert J et al., editors. Ökosystem Darm III. Berlin: Springer; 1991. p. 52-8.